Summary & Overview

Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

DRG 574 applies to inpatient skin grafts for skin ulcers or cellulitis when a Complication or Comorbidity is documented, reflecting higher clinical complexity than cases without such comorbid conditions. This Diagnosis-Related Group influences Medicare inpatient reimbursement by assigning a higher payment weight to account for increased resource use, longer stays, and additional interventions.

Skin Graft for Skin Ulcer or Cellulitis with CCDRG Skin Graft for Skin Ulcer or Cellulitis with CCDRG 574Diagnosis-Related GroupInpatient ReimbursementMedicareWound CareSurgeryPlastic SurgeryInfectious Disease

DRG 574 Overview

DRG 574 covers inpatient admissions for skin graft procedures performed to treat skin ulcers or cellulitis when at least one Complication or Comorbidity is present. Typical cases include surgical debridement and autografting to manage nonhealing pressure, venous, arterial, or diabetic ulcers or extensive infection requiring graft coverage. This Diagnosis-Related Group groups patients with greater resource use than uncomplicated grafts because of increased risk, complexity of wound care, and additional inpatient services. It matters for Medicare payment because the presence of a Complication or Comorbidity elevates relative weight and payment compared with the non-Complication or Comorbidity and Major Complication or Comorbidity categories for similar procedures.

Clinical Trials

Acute surgical technique and perioperative care trials: randomized or prospective cohort studies comparing different skin graft techniques (eg, split-thickness vs full-thickness approaches, variations in donor site preparation, or adjunctive intraoperative wound management) and perioperative protocols (eg, antibiotic prophylaxis duration, wound dressing strategies). These trials enroll hospitalized patients with skin ulcers or cellulitis requiring operative debridement and grafting to assess graft take rates, postoperative infection, and early complication rates. Results inform surgeons and hospital administrators on which operative strategies optimize short-term outcomes and resource use for patients classified under this DRG.
Comparative effectiveness studies of adjunctive wound therapies during inpatient course: pragmatic trials or observational comparative studies evaluating adjuncts such as negative-pressure wound therapy, biologic skin substitutes, or topical antimicrobial agents used alongside grafting in patients with complex ulcers or infected soft tissue. These studies typically include medically complex, often elderly or diabetic patients with comorbidities that impair healing, and they measure time to successful wound closure, reoperation, length of stay, and readmission. Findings are relevant to payers and providers because they help determine which adjunctive approaches improve healing efficiency and reduce inpatient utilization and downstream costs.
Post-discharge outcomes and care coordination research: longitudinal cohort studies or care-pathway trials testing discharge planning, home health integration, and outpatient wound clinic follow-up to reduce readmissions and promote durable graft survival. These studies focus on patients discharged after skin grafting for ulcers or cellulitis, particularly those with social vulnerabilities or limited mobility, tracking wound recurrence, late infections, rehospitalization, and functional status over weeks to months. Evidence from this research informs value-based care strategies, transitional care policies, and reimbursement decisions aimed at lowering preventable readmissions and improving long-term outcomes for this DRG.

Related Codes

571-SKIN-DEBRIDEMENT-WITH-CC

Skin Debridement with CC: Inpatient Reimbursement Overview

594-SKIN-ULCERS-WITHOUT-CC-MCC

Skin Ulcers without CC/MCC: Inpatient Reimbursement Overview

572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

598-MALIGNANT-BREAST-DISORDERS-WITH-CC

Malignant Breast Disorders with CC: Inpatient Reimbursement Overview

580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

570-SKIN-DEBRIDEMENT-WITH-MCC

Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

601-NON-MALIGNANT-BREAST-DISORDERS-WITHOUT-CC-MCC

Non-Malignant Breast Disorders without CC/MCC: Inpatient Reimbursement Overview

602-CELLULITIS-WITH-MCC

Cellulitis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

582-MASTECTOMY-FOR-MALIGNANCY-WITH-CC-MCC

Mastectomy for Malignancy with CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 31

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.